Faropenem Medoxomil
Phase 3Small molecule
Faropenem Medoxomil is one of 51 small molecule programs targeting Chronic Bronchitis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Chronic Bronchitis
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Daliresp
AstraZenecaApproved
Kalydeco
Vertex PharmaceuticalsApproved
Levaquin
WWim Janssens
Approved
Theo-Dur
PfizerApproved
Cipro
BayerApproved
Avelox
BayerPhase 3
Pulmicort
SSalix
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Amoxicillin-Clavulanic Acid
TevaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Faropenem Medoxomil. EMBL-EBI & Wellcome Sanger Institute.
- [4]